TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07553182: Open-label Extension (OLE), Multiple Dose Study to Evaluate Safety, Tolerability, and Efficacy of Filgotinib in Children and Adolescents From 8 Years to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis (JIA)

Sponsor: Alfasigma S.p.A. · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 80 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,757,600

Rescue Site Savings

+$7,740,420

Unlock Full NCT07553182 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07553182 Rescue Dossier →